Entrada Therapeutics Inc 2024年度报告

FORM10-K (Mark One) For the transition period from to Commission File Number:001-40969ENTRADA THERAPEUTICS, INC. Securities registered pursuant to Section 12(b) of the Act: Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or forsuch shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of thischapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See thedefinitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting underSection 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.¨ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error topreviously issued financial statements.¨ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executiveofficers during the relevant recovery period pursuant to §240.10D-1(b).¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The aggregate market value of registrant’s common equity held by non-affiliates of registrant on June 30, 2024 was approximately $392.5million based upon the closing sale price of thecommon stock as reported on The Nasdaq Global Market as of June 28, 2024 (the last business day of the registrant's most recently completed second fiscal quarter). In determining the marketvalue of non-affiliate common stock, shares of the registrant’s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status isnot necessarily a conclusive determination for other purposes. As of February 20, 2025, the registrant had37,594,630shares of common stock, $0.0001 par value per share, outstanding. DOCUMENTS INCORPORATED BY REFERENCE TABLE OF CONTENTS PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities107Item 6.Reserved108Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations108Item 7A.Quantitative and Qualitative Disclosures About Market Risk119Item 8.Financial Statements and Supplementary Data120Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure151Item 9A.Controls and Procedures151Item 9B.Other Information151Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections152 PART III Item 10.Directors, Executive Officers and Corporate Governance153Item 11.Executive Compensation153Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters153Item 13.Certain Relationships and Related Transactions, and Director Independence153Item 14.Principal Accounting Fees and Services153 PART IV Item 15.Exhibits and Financial Statement SchedulesItem 16.Form 10-K SummarySignatures 154156157 From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/entradatx to distribute materialinformation. Our financial and other material information is routinely posted to and accessible on the Inv